Skip to main content
BMC Genomics logoLink to BMC Genomics
. 2009 Feb 24;10:90. doi: 10.1186/1471-2164-10-90

Expression profiling and Ingenuity biological function analyses of interleukin-6- versus nerve growth factor-stimulated PC12 cells

Dieter Kunz 1,✉,#, Gaby Walker 2,#, Marc Bedoucha 3, Ulrich Certa 4, Pia März-Weiss 2, Beatrice Dimitriades-Schmutz 1, Uwe Otten 1
PMCID: PMC2657914  PMID: 19239705

Abstract

Background

The major goal of the study was to compare the genetic programs utilized by the neuropoietic cytokine Interleukin-6 (IL-6) and the neurotrophin (NT) Nerve Growth Factor (NGF) for neuronal differentiation.

Results

The designer cytokine Hyper-IL-6 in which IL-6 is covalently linked to its soluble receptor s-IL-6R as well as NGF were used to stimulate PC12 cells for 24 hours. Changes in gene expression levels were monitored using Affymetrix GeneChip technology. We found different expression for 130 genes in IL-6- and 102 genes in NGF-treated PC12 cells as compared to unstimulated controls. The gene set shared by both stimuli comprises only 16 genes.

A key step is upregulation of growth factors and functionally related external molecules known to play important roles in neuronal differentiation. In particular, IL-6 enhances gene expression of regenerating islet-derived 3 alpha (REG3A; 1084-fold), regenerating islet-derived 3 beta (REG3B/PAPI; 672-fold), growth differentiation factor 15 (GDF15; 80-fold), platelet-derived growth factor alpha (PDGFA; 69-fold), growth hormone releasing hormone (GHRH; 30-fold), adenylate cyclase activating polypeptide (PACAP; 20-fold) and hepatocyte growth factor (HGF; 5-fold). NGF recruits GDF15 (131-fold), transforming growth factor beta 1 (TGFB1; 101-fold) and brain-derived neurotrophic factor (BDNF; 89-fold). Both stimuli activate growth-associated protein 43 (GAP-43) indicating that PC12 cells undergo substantial neuronal differentiation.

Moreover, IL-6 activates the transcription factors retinoic acid receptor alpha (RARA; 20-fold) and early growth response 1 (Egr1/Zif268; 3-fold) known to play key roles in neuronal differentiation.

Ingenuity biological function analysis revealed that completely different repertoires of molecules are recruited to exert the same biological functions in neuronal differentiation. Major sub-categories include cellular growth and differentiation, cell migration, chemotaxis, cell adhesion, small molecule biochemistry aiming at changing intracellular concentrations of second messengers such as Ca2+ and cAMP as well as expression of enzymes involved in posttranslational modification of proteins.

Conclusion

The current data provide novel candidate genes involved in neuronal differentiation, notably for the neuropoietic cytokine IL-6. Our findings may also have impact on the clinical treatment of peripheral nerve injury. Local application of a designer cytokine such as H-IL-6 with drastically enhanced bioactivity in combination with NTs may generate a potent reparative microenvironment.

Background

Interleukin-6 (IL-6) is the prototype member of the IL-6 cytokine family, also termed neuropoietic cytokines, including IL-6, IL-11, IL-27, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M, cardiotrophin-1 (CT-1), cardiotrophin-like cytokine (CLC; also known as novel neurotrophin 1, NNT1), neuropoietin and B cell stimulatory factor 3 (BSF3) [1,2]. A common feature of all family members is the signaling through a specific receptor that is associated to the intracellularly located transduction component gp130. Subsequently, the Janus-activated kinase-signal transducer, activator of transcription (JAK-STAT) and mitogen-activated protein kinase (MAPK) signal transduction pathways are activated. Neuropoietic cytokines display multiple functions in the peripheral (PNS) and central nervous systems (CNS), including the developing and adult brain, synaptic plasticity as well as the brain's response to injury and disease. In particular these molecules control cell fate and differentiation of neural stem and progenitor cells during development; due to their neurotrophic and regenerative actions they crucially affect injury-induced neurogenesis, neuronal survival and regeneration; moreover, these molecules can also influence neuronal activity and are implicated in long-term potentiation (LTP; reviewed in [2]).

Cellular functions of IL-6 are mediated by two specific receptors, the membrane-bound 80 KDa IL-6 receptor (IL-6R) or the soluble form of IL-6R (s-IL-6R) which can be generated either by shedding of IL-6R or by alternative splicing of the IL-6R mRNA [3,4]. Using s-IL-6R, IL-6 responsiveness may be conferred to cells expressing the transduction component gp130, but are devoid of membrane-bound IL-6R in the process of transsignaling [5-7]. The transsignaling mechanism led to the development of a fusion protein in which IL-6 is covalently linked to s-IL-6R thereby creating a unimolecular protein with enhanced biological activities. The fusion protein, termed Hyper-IL-6 (H-IL-6), turned out to be fully active at 100–1000-fold lower concentrations as compared to the combination of the two separate molecules [8,9].

The neurotrophin (NT) family of growth factors including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and NT-4/5 is important for development, maintenance and survival of many different cell types in the PNS and the CNS [10]. NTs are also involved in regulating adult neurogenesis [11,12], learning and memory [13,14]. NTs are synthesized as proNT precursors that may be processed to mature NTs intra- and extracellulary by specific proteases [15]. NTs exert their effects via two different types of cellular receptors: pan-neurotrophin receptor p75 (p75NTR) which binds all NTs with a similar affinity, and the family of high affinity tyrosine kinase receptors (Trk). The interactions of proNTs and NTs with the NT-receptors comprise a complex signaling system thus generating a broad variety of biological effects [16,17].

In the first report of IL-6 actions on neural cells rat pheochromocytoma cells (PC12), a well characterised cellular model for neuronal differentiation, were incubated for up to 6 days with B-cell stimulatory factor BSF-2/IL-6 thereby inducing significant neurite outgrowth [18]. PC12 cells that were differentiated either using irradiation [19] or the well-known hypoxia mimetic agent CoCl2 [20] require IL-6 expression. We have demonstrated that primary sympathetic neurons [21] and PC12 cells [22] can strongly respond to IL-6 by transsignaling, and that the potential of IL-6 to induce neuronal differentiation in PC12 cells is in close correlation to the availability of s-IL-6R [22,23]. PC12 cell differentiation is accompanied by enhanced expression of GAP-43 mRNA at 24 hours after stimulation with IL-6/s-IL-6R [22]. Moreover, we found that the fusion protein H-IL-6 is a highly active molecule in inducing survival of cultured sympathetic neurons, comparable to the effects of NGF [21,22]. Recently, IL6RIL6, a fusion protein in which IL-6 is directly linked to the extracellular domain of the IL-6 specific receptor, has been used for expression profiling studies in primary cultures of dorsal root ganglia. In these cells, IL6RIL6 strongly increases axonal network and expression of neural genes [24].

A significant problem in the clinical treatment of peripheral nerve injury is that the currently used therapeutic approaches do not allow complete neuronal recovery [25]. Mixtures comprising neuropoietic cytokines, glial cell-line derived neurotrophic factor ligands (GFLs) and NTs are being tested for the suitability to generate a microenvironment with a high reparative potential upon local administration at the site of the lesion [26].

In the present study we monitored changes in neuronal gene expression induced by incubation of PC12 cells for 24 hours with H-IL-6 as well as NGF, and compared the genetic programs utilized by these stimuli for neuronal differentiation.

Results

Overall changes in gene expression patterns in IL-6- and NGF-stimulated PC12 cells

Affymetrix Gene Chip U34A arrays were used to analyse global changes in gene transcripts using a cutoff in the change of gene expression of > 2-fold. In PC12 cells stimulated for 24 h with 10 ng/ml H-IL-6, we found 130 differently expressed genes as compared to unstimulated controls. Of them, 94 genes were upregulated with gene expression values from 2-fold to 1085-fold, whereas 36 genes were found to be downregulated in the range from -2-fold to -61-fold. The genes are further classified into major functional categories including cytokines (2 up-regulated/0 down-regulated), enzymes (20/8), G-protein coupled receptors (2/3), growth factors (7/1), ion channels (2/0), kinases (4/4), nuclear receptors (2/1), peptidases (3/1), phosphatases (0/2), transcription regulators (8/4), transmembrane receptors (5/0), transporters (8/3) and molecules with other functions (31/9; Table 1).

Table 1.

List of gene set regulated by IL-6 in PC12 cells

Gene Accession no. Fold change Subcellular location
Cytokines
 chemokine ligand 13 CXCL13 AF044196 43 Extracellular Space
 chemokine ligand 10 CXCL10 U17035 7 Extracellular Space
Enzymes
 cytochrome P450, 4f16 CYP4F16 U39207 424 Cytoplasm
 ceruloplasmin CP AF202115 191 Extracellular Space
 peptidyl arginine deiminase, type III PADI3 D88034 142 Cytoplasm
 acyl-CoA synthetase, member 1 ACSL1 D90109 102 Cytoplasm
 transglutaminase 1 TGM1 M57263 93 Plasma Membrane
 nitric oxide synthase 2A NOS2A U03699 58 Cytoplasm
 ornithine carbamoyltransferase OTC M11266 43 Cytoplasm
 Similar to Lysophospholipase LOC374569 AB009372 37 Unknown
 trehalase TREH AF038043 35 Plasma Membrane
 kynureninase KYNU U68168 25 Cytoplasm
 nitric oxide synthase 3 NOS3 AJ011115 21 Cytoplasm
 glycine amidinotransferase GATM U07971 14 Cytoplasm
 guanine nucleotide binding protein, alpha z GNAZ U77485 14 Plasma Membrane
 ST6 galactosamide alpha-2,6-sialyltranferase 1 ST6GAL1 M83143 14 Cytoplasm
 aldo-keto reductase, 1C1 AKR1C1 BAA92883 12 Cytoplasm
 myxovirus resistance 1 MX1 P20591 9 Nucleus
 aldolase C ALDOC X06984 3 Cytoplasm
 2',5'-oligoadenylate synthetase 1 OAS1 Z18877 3 Cytoplasm
 protein disulfide isomerise, A2 PDIA2 AAC50401 3 Cytoplasm
 RNA (guanine-7-) methyltransferase RNMT BAA82447 3 Nucleus
 polymerase, alpha 2 POLA2 AJ245648 -2 Nucleus
 steroid-5-alpha-reductase, alpha 1 SRD5A1 J05035 -2 Cytoplasm
 aminolevulinate, delta-, synthase 2 ALAS2 D86297 -3 Cytoplasm
 glutathione S-transferase A3 GSTA3 X78847 -3 Cytoplasm
 UDP glycosyltransferase 8 UGT8 BC075069 -3 Cytoplasm
 cell division cycle 42 CDC42 U37720 -4 Cytoplasm
 cysteine dioxygenase, type I CDO1 M35266 -4 Cytoplasm
 ST8 alpha-2,8-sialyltransferase 3 ST8SIA3 X80502 -5 Cytoplasm
G-protein coupled receptors
 adrenergic receptor, alpha-2B ADRA2B M32061 26 Plasma Membrane
 arginine vasopressin receptor 2 AVPR2 AAB87678 5 Plasma Membrane
 vasoactive intestinal peptide receptor 1 VIPR1 M86835 -2 Plasma Membrane
 cholinergic receptor, muscarinic 3 CHRM3 AB017656 -3 Plasma Membrane
 cholinergic receptor, muscarinic 4 CHRM4 M16409 -10 Plasma Membrane
Growth factors
 regenerating islet-derived 3 alpha REG3A L10229 1084 Extracellular Space
 regenerating islet-derived 3 beta REG3B S43715 672 Extracellular Space
 growth differentiation factor 15 GDF15 AJ011970 80 Extracellular Space
 platelet-derived growth factor alpha PDGFA M29464 69 Extracellular Space
 nudix-type motif 6 NUDT6 AF188995 22 Extracellular Space
 jagged 2 JAG2 U70050 5 Extracellular Space
 hepatocyte growth factor HGF X84046 4 Extracellular Space
 macrophage stimulating 1 MST1 X95096 -4 Extracellular Space
Ion channels
 glutamate receptor, ionotropic, delta 2 GRID2 U08256 91 Plasma Membrane
 purinergic receptor P2X P2RX2 Y10475 11 Plasma Membrane
Kinases
 fyn-related kinase FRK U02888 122 Nucleus
 Janus kinase 2 JAK2 U13396 120 Cytoplasm
 phosphatidylinositol 4-kinase beta PI4KB D84667 2 Cytoplasm
 pim-3 oncogene PIM3 AF086624 2 Unknown
 fer tyrosine kinase FER X13412 -2 Cytoplasm
 mitogen-activated protein kinase kinase 5 MAP2K5 U37462 -2 Cytoplasm
 fibroblast growth factor receptor 1 FGFR1 S54008 -3 Plasma Membrane
 activin receptor, type IIA ACVR2A S48190 -4 Plasma Membrane
Nuclear receptors
 retinoic acid receptor alpha RARA U15211 20 Nucleus
 nuclear receptor, *C2 NR3C2 M36074 8 Nucleus
 vitamin D receptor VDR J03630 -4 Nucleus
Peptidases
 complement component 1s C1S D88250 230 Extracellular Space
 caspase 1 CASP1 U14647 40 Cytoplasm
 proteasome subunit, alpha 1 PSMA1 M29859 5 Cytoplasm
 kallikrein-related peptidase 8 KLK8 AJ005641 -5 Extracellular Space
Phosphatases
 pyruvate dehydrogenase phosphatase 2 PDP2 AF062741 -4 Cytoplasm
 protein tyrosine phosphatase receptor D PTPRD U57502 -9 Plasma Membrane
Transcription regulators
 signal transducer and activator of transcription 1 STAT1 AF205604 579 Nucleus
 Kruppel-like factor 6 KLF6 AF072403 249 Nucleus
 HIV-1 Tat interacting protein HTATIP AAB18236 159 Nucleus
 HIV enhancer binding protein 2 HIVEP2 D37951 65 Nucleus
 upstream transcription factor 1 USF1 U41741 22 Nucleus
 early growth response 1 EGR1 M18416 3 Nucleus
 interferon regulatory factor 1 IRF1 M34253 3 Nucleus
 signal transducer and activator of transcription 2 STAT2 AF206162 3 Nucleus
 breast cancer 1 BRCA1 U36475 -2 Nucleus
 D site of albumin promoter binding protein DBP J03179 -2 Nucleus
 nuclear factor I/B NFIB Y07685 -2 Nucleus
 transcription elongation factor A 2 TCEA2 D12927 -5 Nucleus
Transmembrane receptors
 oxidized low density lipoprotein receptor 1 OLR1 AB018097 587 Plasma Membrane
 histocompatibility 2, Q region locus 10 H2-Q10 M31018 160 Plasma Membrane
 insulin-like growth factor 2 receptor IGF2R NM_000876 39 Plasma Membrane
 Fc fragment of IgG receptor IIa (CD32) FCGR2A M64368 16 Plasma Membrane
 growth hormone receptor GHR Z83757 12 Plasma Membrane
Transporters
 cadherin 17 CDH17 X78997 273 Plasma Membrane
 solute carrier family 6, member 3 SLC6A3 M80570 90 Plasma Membrane
 nucleoporin 153kDa NUP153 L06821 83 Nucleus
 solute carrier family 9, member 2 SLC9A2 L11004 32 Plasma Membrane
 cadherin 17 CDH17 L46874 13 Plasma Membrane
 lipocalin 2 LCN2 X13295 9 Extracellular Space
 syntaxin 4 STX4 L20821 3 Plasma Membrane
 secretory carrier membrane protein 2 SCAMP2 AF295405 2 Cytoplasm
 solute carrier family 12, member 5 SLC12A5 U55816 -3 Plasma Membrane
 solute carrier family 30, member 2 SLC30A2 U50927 -5 Plasma Membrane
 syntaxin 5 STX5 U87971 -8 Cytoplasm
Others
 regenerating islet-derived 1 alpha REG1A J05722 796 Extracellular Space
 TIMP metallopeptidase inhibitor 1 TIMP1 L31883 210 Extracellular Space
 calcitonin-related polypeptide beta CALCB M11596 195 Extracellular Space
 fibrinogen gamma chain FGG J00734 164 Extracellular Space
 trans-golgi network protein 2 TGOLN2 X53565 113 Cytoplasm
 LIM and senescent cell antigen-like domains 1 LIMS1 AAA20086 94 Plasma Membrane
 alpha-2-HS-glycoprotein AHSG M29758 80 Extracellular Space
 ribosomal protein L3-like RPL3L AAC50777 60 Unknown
 collagen, type IV, alpha 5 COL4A5 AB041350 59 Extracellular Space
 parvalbumin LOC4951 J02705 58 Unknown
 YTH domain containing 1 YTHDC1 AF144731 39 Cytoplasm
 growth hormone releasing hormone GHRH Z34092 31 Extracellular Space
 annexin A1 ANXA1 M19967 29 Plasma Membrane
 collagen, type XII, alpha 1 COL12A1 U57362 26 Extracellular Space
 regenerating islet-derived 3 gamma REG3G L20869 24 Extracellular Space
 adenylate cyclase activating polypeptide 1 ADCYAP1 S83513 20 Extracellular Space
 heat shock protein 90 kDa, alpha B 1 HSP90AB1 S45392 20 Cytoplasm
 luteinizing hormone beta LHB U25653 17 Extracellular Space
 galectin 5 LGALS5 L36862 8 Extracellular Space
 myocilin MYOC AF093567 8 Cytoplasm
 prolactin family 8a81 PRL8A8 AB000107 8 Extracellular Space
 troponin C type 2 TNNC2 J05598 8 Unknown
 ribosomal protein L18a RPL18A X14181 7 Cytoplasm
 fibrinogen beta chain FGB U05675 6 Extracellular Space
 tropomyosin 3 TPM3 X72859 4 Cytoplasm
 tubulin, beta TUBB AB011679 4 Cytoplasm
 extracellular proteinase inhibitor EXPI X13309 3 Extracellular Space
 growth associated protein 43 GAP43 M16736 3 Plasma Membrane
 galectin 9 LGALS9 U72741 3 Extracellular Space
 tubulin, alpha 4a TUBA4A M13444 3 Cytoplasm
 BCL2-like 11 BCL2L11 AF136927 2 Cytoplasm
 integrin alpha 7 ITGA7 X65036 -2 Plasma Membrane
 syndecan 2 SDC2 M81687 -2 Plasma Membrane
 zinc finger protein 260 ZNF260 U56862 -2 Nucleus
 filamin C FLNC AF119148 -3 Cytoplasm
 metallothionein 3 MT3 S65838 -3 Cytoplasm
 arginine vasopressin AVP M25646 -4 Extracellular Space
 fasciculation and elongation protein zeta 1 FEZ1 U63740 -4 Cytoplasm
 crystallin, alpha B CRYAB U04320 -6 Nucleus
 neurofascin NFASC U81036 -7 Plasma Membrane

Gene description names, gene symbols are from IPA Tool; accession numbers are from GenBank

In PC12 cells stimulated for 24 hours with 50 ng/ml NGF, we identified 102 differently expressed genes as compared to unstimulated controls. Of them, 71 genes were upregulated with gene expression values from 2-fold to 303-fold, whereas 31 genes were found to be downregulated by -2-fold to -20-fold. Major functional categories include enzymes (18 up-regulated/9 down-regulated), G-Protein coupled receptors (2/2), growth factors (3/1), ion channels (7/2), kinases (6/2), peptidases (4/1), phosphatases (2/1), transcription regulators (0/2), transmembrane receptors (1/0), transporters (9/2) and molecules with other functions (21/9; Table 2).

Table 2.

List of gene set regulated by NGF in PC12 cells

Gene Accession no. Fold change Subcellular location
Enzymes
 rat senescence marker protein 2A gene SMP2A X63410 303 Cytoplasm
 myosin, heavy chain 3 MYH3 K03468 133 Cytoplasm
 lecithin-cholesterol acyltransferase LCAT X54096 101 Extracellular Space
 UDP glucuronosyltransferase 2, polypeptide A1 UGT2A1 X57565 63 Cytoplasm
 contactin 4 CNTN4 U35371 44 Plasma Membrane
 phosphodiesterase 4B, PDE4B J04563 37 Cytoplasm
 gulonolactone (L-) oxidase GULO J03536 34 Cytoplasm
 superoxide dismutase 3 SOD3 Z24721 28 Extracellular Space
 fibronectin 1 FN1 X15906 28 Plasma Membrane
 acetylcholinesterase ACHE S50879 28 Plasma Membrane
 tryptophan hydroxylase 1 TPH1 X53501 24 Cytoplasm
 aldo-keto reductase family 1, member C1 AKR1C1 BAA92883 10 Cytoplasm
 guanine nucleotide binding protein, alpha z GNAZ U77485 9 Plasma Membrane
 aminoadipate aminotransferase AADAT Z50144 5 Cytoplasm
 phospholipase D2 PLD2 D88672 4 Cytoplasm
 N-deacetylase/N-sulfotransferase 1 NDST1 M92042 3 Cytoplasm
 phosphate cytidylyltransferase 2 PCYT2 AF080568 2 Cytoplasm
 peptidylprolyl isomerase A PPIA M19533 -2 Cytoplasm
 Rab geranylgeranyltransferase alpha RABGGTA L10415 -2 Unknown
 glutathione S-transferase A3 GSTA3 X78847 -3 Cytoplasm
 cytochrome P450, 4F4 CYP4F4 U39206 -3 Cytoplasm
 3-hydroxyanthranilate 3,4-dioxygenase HAAO D28339 -3 Cytoplasm
 stearoyl-Coenzyme A desaturase 2 SCD2 AB032243 -4 Cytoplasm
 aldo-keto reductase family 1, member C3 AKR1C3 L32601 -6 Cytoplasm
 myxovirus resistance 2 MX2 X52711 -10 Nucleus
 serine dehydratase SDS M38617 -11 Cytoplasm
G-protein coupled receptors
 calcitonin/calcitonin-related polypeptide alpha CALCA V01228 136 Plasma Membrane
 angiotensin II receptor 1 AGTR1 NM_009585 50 Plasma Membrane
 cholinergic receptor, muscarinic 3 CHRM3 AB017656 -2 Plasma Membrane
 parathyroid hormone receptor 1 PTHR1 M77184 -3 Plasma Membrane
Growth factors
 growth differentiation factor 15 GDF15 AJ011970 131 Extracellular Space
 transforming growth factor beta 1 TGFB1 X52498 101 Extracellular Space
 brain-derived neurotrophic factor BDNF X67108 89 Extracellular Space
 neuregulin 1 NRG1 U02324 -3 Extracellular Space
Ion channels
 calcium channel, voltage-dependent, beta 2 CACNB2 M80545 90 Plasma Membrane
 glutamate receptor, ionotropic, delta 2 GRID2 U08256 78 Plasma Membrane
 sodium channel, voltage-gated, type II, beta SCN2B U37147 73 Plasma Membrane
 potassium inwardly-rectifying channel J4 KCNJ4 X87635 51 Plasma Membrane
 solute carrier family 9 member 3 SLC9A3 M85300 40 Plasma Membrane
 purinergic receptor P2X, ligand-gated ion channel 2 P2RX2 Y10475 13 Plasma Membrane
 sodium channel, voltage-gated, type I, alpha SCN1A M22253 12 Plasma Membrane
 purinergic receptor P2X-like 1 P2RXL1 X92070 -2 Plasma Membrane
 gamma-aminobutyric acid A receptor gamma 2 GABRG2 X56313 -19 Plasma Membrane
Kinases
 G protein-coupled receptor kinase 5 GRK5 NM_005308 131 Plasma Membrane
 protein kinase, cGMP-dependent, type II PRKG2 Z36276 68 Cytoplasm
 mitogen-activated protein kinase kinase kinase kinase 1 MAP4K1 Y09010 25 Cytoplasm
 calcium/calmodulin-dependent serine protein kinase CASK U47110 3 Plasma Membrane
 discs, large homolog 1 DLG1 U14950 3 Plasma Membrane
 phosphatidylinositol 4-kinase beta PI4KB D84667 3 Cytoplasm
 discoidin domain receptor family member 1 DDR1 L26525 -8 Plasma Membrane
 non-metastatic cells 6 NME6 AF051943 -14 Extracellular Space
Peptidases
 carboxypeptidase A3 CPA3 U67914 5 Extracellular Space
 ADAM metallopeptidase domain 17 ADAM17 AJ012603 4 Plasma Membrane
 Proteasome subunit alpha 1 PSMA1 M29859 3 Cytoplasm
 protein disulfide isomerase family A member 3 PDIA3 D63378 2 Cytoplasm
 caspase 1 CASP1 U14647 -5 Cytoplasm
Phosphatases
 dual specificity phosphatase 6 DUSP6 U42627 53 Cytoplasm
 protein phosphatase 1 subunit 1A PPP1R1A AJ276593 18 Cytoplasm
 protein tyrosine phosphataser type 11 PTPN11 U09307 -2 Cytoplasm
Transcription regulators
 jun dimerization protein 2 JDP2 U53449 -2 Nucleus
 cAMP responsive element modulator CREM Z15158 -4 Nucleus
Transmembrane receptors
 cholinergic receptor, nicotinic, beta 1 CHRNB1 X74833 39 Plasma Membrane
Transporters
 solute carrier family 1 member 1 SLC1A1 U21104 238 Plasma Membrane
 solute carrier family 22, member 3 SLC22A3 AF055286 95 Plasma Membrane
 gap junction protein, beta 2 GJB2 X51615 55 Plasma Membrane
 solute carrier family 1, member 3 SLC1A3 S59158 6 Plasma Membrane
 solute carrier family 22, member 6 SLC22A6 AF008221 6 Plasma Membrane
 vacuolar protein sorting 33 homolog B VPS33B U35245 4 Cytoplasm
 solute carrier family 30, member 1 SLC30A1 U17133 3 Plasma Membrane
 syntaxin 4 STX4 L20821 2 Plasma Membrane
 murinoglobulin 1 MUG1 J03552 -2 Extracellular Space
 ATPase, Cu++ transporting, beta polypeptide ATP7B AF120492 -6 Cytoplasm
Others
 BCL2/adenovirus E1B interacting protein 3 BNIP3 AF243515 216 Cytoplasm
 natriuretic peptide precursor C NPPC D90219 109 Extracellular Space
 trans-golgi network protein 2 TGOLN2 X53565 106 Cytoplasm
 fibrillin 2 FBN2 L39790 105 Extracellular Space
 amyloid P component, serum APCS M83177 85 Extracellular Space
 zinc finger, matrin type 3 ZMAT3 Y13148 84 Nucleus
 LIM and senescent cell antigen-like domains 1 LIMS1 AAA20086 75 Plasma Membrane
 CD44 molecule CD44 U96138 61 Plasma Membrane
 common salivary protein 1 LOC171161 U00964 54 Extracellular Space
 selectin P SELP L23088 44 Plasma Membrane
 collagen, type XI, alpha 1 COL11A1 AJ005396 39 Extracellular Space
 collagen, type XII, alpha 1 COL12A1 U57362 28 Extracellular Space
 nucleosome assembly protein 1-like 4 NAP1L4 AJ002198 22 Nucleus
 spermine binding protein SBP J02675 20 Unknown
 ribosomal protein L35 RPL35 M34331 6 Cytoplasm
 connector enhancer of kinase suppressor of Ras 2 CNKSR2 AF102854 5 Plasma Membrane
 prolactin family 8, subfamily a, member 81 PRL8A8 AB000107 4 Extracellular Space
 extracellular proteinase inhibitor EXPI X13309 3 Extracellular Space
 fibrinogen gamma chain FGG J00735 3 Extracellular Space
 smooth muscle alpha-actin ACTA2 X06801 2 Unknown
 tropomyosin 1 alpha TPM1 M34134 2 Cytoplasm
 calcineurin binding protein 1 CABIN1 AF061947 -2 Nucleus
 crystallin, gamma E CRYGE J00716 -2 Unknown
 follistatin-like 1 FSTL1 M91380 -2 Extracellular Space
 secreted phosphoprotein 2 SPP2 U19485 -2 Extracellular Space
 tachykinin, precursor 1 TAC1 M15191 -2 Extracellular Space
 myosin light chain 9 MYL9 S77900 -3 Cytoplasm
 ubiquitin B UBB X51703 -3 Cytoplasm
 golgin B1 protein GOLGB1 D25543 -6 Cytoplasm
 lysosomal-associated membrane protein 1 LAMP1 X14765 -11 Plasma Membrane

Gene description names, gene symbols are from IPA Tool; accession numbers are from GenBank

Only a small overlapping gene subset is shared by IL-6 and NGF comprising a total of 16 genes and including the major functional categories enzymes (3 genes), G-Protein coupled receptors (1), growth factors (1), ion channels (2), kinases (1), peptidases (2), transporters (1) and molecules with other functions (5; Table 3). All genes are regulated in a parallel fashion except for caspase 1 with an opposite expression pattern of IL-6 (40-fold) as compared to NGF (-5-fold; Table 3). Tables 1, 2, 3 summarize gene description names, Genbank accession numbers and changes in expression levels derived from the Chip analyses, gene symbols and abbreviations derived from the IPA Tool.

Table 3.

Set of genes commonly regulated by IL-6 and NGF in PC12 cells

Gene Fold change
IL-6 NGF
Enzymes
 guanine nucleotide binding protein, alpha z GNAZ 14 9
 glutathione S-transferase A3 GSTA3 - 3 - 3
 aldo-keto reductase family 1, member C1 AKR1C1 12 10
G-protein coupled receptors
 cholinergic receptor, muscarinic 3 CHRM3 - 3 - 2
Growth factors
 growth differentiation factor 15 GDF15 80 131
Ion channels
 glutamate receptor, ionotropic, delta 2 GRID2 91 78
 purinergic receptor P2X, ligand-gated ion channel P2RX2 11 13
Kinases
 phosphatidylinositol 4-kinase beta PI4KB 2 3
Peptidases
 caspase 1 CASP1 40 - 5
 proteasome subunit alpha 1 PSMA1 5 3
Transporters
 syntaxin 4 STX4 3 2
Others
 trans-golgi network protein 2 TGOLN2 113 106
 LIM and senescent cell antigen-like domains 1 LIMS1 94 75
 fibrinogen gamma chain FGG 94 3
 collagen, type XII, alpha 1 COL12A1 26 28
 extracellular proteinase inhibitor EXPI 3 3

Gene description names, gene symbols are from IPA Tool

Exemplary validation of microarray data using LightCycler quantitative RT-PCR analyses (qRT-PCR) on GAP-43 and REG3B mRNA expression

For an exemplary validation of the microarray data, qRT-PCR using LightCycler was performed on GAP-43 and REG3B mRNA expression. In the microarray analyses, GAP-43 mRNA was found to be upregulated 3-fold by IL-6 (Table 1), whereas qRT-PCR revealed an induction of about 20-fold (Figure 1, left). In NGF-treated PC12 cells, GAP-43 mRNA was found to be upregulated by < 2-fold and therefore did not meet the exclusion criteria applied in the current work. However, qRT-PCR analyses revealed a 10-fold induction of GAP-43 mRNA levels induced by NGF in PC12 cells (Figure 2). Thus, PC12 cells treated with IL-6 or NGF undergo substantial neuronal differentiation. REG3B mRNA expression in the microarray analysis was found to be induced to 672-fold by IL-6 (Table 1), whereas qRT-PCR revealed an induction of REG3B mRNA by about 955-fold (Figure 1, right). In NGF-treated PC12 cells, neither microarray nor qRT-PCR analyses revealed changes in RGE3B expression.

Figure 1.

Figure 1

Changes in expression of GAP-43- and REG3B mRNA levels in IL-6-stimulated PC12 cells determined by qRT-PCR versus GeneChip. Affymetrix Genechip- and qRT-PCR analyses were performed as described in the Methods section.

Figure 2.

Figure 2

Changes in expression of GAP-43- mRNA levels in IL-6- versus NGF-stimulated PC12 cells. qRT-PCR analyses were performed as described in the Methods section.

Ingenuity biological functional analyses of the gene sets regulated by IL-6 and NGF in PC12 cells

The criteria applied for the search of major biological function categories were maximum number of genes and the p-value of significance. As shown in Table 4, top biological functions found to be regulated by IL-6 include cancer (61 genes), cellular growth and proliferation (54 genes), cell death (47 genes), cell-to-cell signalling and interaction (46 genes), tissue development (45 genes) and others. A further gene set is involved in nervous system development and function (24 genes). The p-values in the range of 2.26 × 10-7 to 3.77 × 10-3 indicate statistical significance.

Table 4.

Top high-level functions identified by Ingenuity global function analysis of regulated genes in IL-6-versus NGF- stimulated PC 12 cells

Biological function classification Number of genes Significance (p-value)
IL-6-regulated genes
Cancer 61 2.98 × 10-6 to 5.16 × 10-3
Cellular Growth and Proliferation 54 1.14 × 10-6 to 5.16 × 10-3
Cell Death 47 4.54 × 10-6 to 5.16 × 10-3
Cell-to-Cell Signalling and Interaction 46 2.26 × 10-7 to 5.16 × 10-3
Tissue Development 45 2.26 × 10-7 to 5.15 × 10-3
Cellular Movement 39 9.19 × 10-6 to 5.16 × 10-3
Cellular Development 38 8.56 × 10-6 to 4.85 × 10-3
Small Molecule Biochemistry 37 1.32 × 10-5 to 4.47 × 10-3
...
Nervous system development and function 24 2.83 × 10-5 to 3.77 × 10-3
NGF-regulated genes
Cellular growth and proliferation 37 7.86 × 10-5 to 8.88 × 10-3
Cell-to-cell signalling and interaction 31 1.03 × 10-4 to 7.43 × 10-3
Molecular transport 30 8.89 × 10-6 to 8.70 × 10-3
Cancer 30 1.03 × 10-4 to 7.43 × 10-3
Cellular movement 29 2.41 × 10-5 to 8.70 × 10-3
Cell death 29 2.73 × 10-5 to 8.77 × 10-3
Neurological diseases 29 1.07 × 10-4 to 8.70 × 10-3
Nervous system development and function 29 1.60 × 10-4 to 8.70 × 10-3

p-values are from IPA Tool

Similarly, in NGF-treated PC12 cells top biological functions deal with the overall topics on cellular growth and proliferation (37 genes), cell-to-cell signalling and interaction (31 genes), molecular transport (30 genes), cancer (30 genes), cellular movement (29 genes) and others. One gene set is involved in nervous system development and function (29 genes). The p-values in the range from 8.89 × 10-6 to 7.43 × 10-3 indicate statistical significance (Table 4).

More detailed analyses for functional sub-categories are summarized in Table 5. Both stimuli utilize different repertoires of genes to exert the same biological functions that are all crucial for neuronal differentiation and nervous system development. Among others, important functional sub-categories include cellular growth (IL-6, 33 genes; NGF, 24 genes), differentiation (IL-6, 45 genes; NGF, 16 genes), cell movement (IL-6, 39 genes; NGF, 27 genes), chemotaxis (IL-6, 13 genes; NGF, 13 genes), adhesion of cells (IL-6, 26 genes; NGF, 18 genes), cellular signalling and small molecule biochemistry aiming at changing intracellular concentrations of second messengers such as Ca2+ (IL-6, 16 genes; NGF, 16 genes) as well as cAMP (IL-6, 12 genes; NGF, 9 genes) as well as expression of posttranslational processing enzymes (IL-6, 23 genes; NGF, 15 genes). Table 5 (bottom) summarizes genes involved in specialized sub-categories of nervous system and development as far as they are represented in the IPKB.

Table 5.

Ingenuity biological function analyses of IL-6-versus NGF-regulated genes in PC12 cells (selected)

IL-6 regulated genes in PC12 cells NGF-regulated genes in PC12 cells
Category p-value Molecules p-value Molecules
Sub-Category or Function annotation
Cellular Growth and Proliferation
Growth of cells 2.27 × 10-4 ACVR2A, AHSG, ANXA1, BCL2L11, BRCA1, CASP1, CDC42, CHRM3, CXCL10, EGR1, FGFR1, GAP43, GDF15, GHR, GRID2, HGF, IGF2R, IRF1, ITGA7, JAK2, MAP2K5, MST1, MT3, MX1, NOS3, NOS2A, PIM3, RARA, SCAMP2, SDC2, STAT1, TIMP1, VDR 8.82 × 10-3 ACHE, AGTR1, BDNF, BNIP3, CASP1, CD44, CHRM3, CREM, DDR1, DUSP6, FBN2, FN1, GDF15, GJB2, GRID2, MYL9, NRG1, PDIA3, PTPN11, SLC30A1, TGFB1, TPM1, VPS33B, ZMAT3
Proliferation of cells 9.06 × 10-7 ACVR2A, ADCYAP1, ANXA1, AVP, BCL2L11, BRCA1, CALCB, CDC42, CHRM3, CHRM4, CRYAB, CXCL10, EGR1, FGFR1, FRK, GDF15, GHR, GHRH, HGF, IGF2R, IRF1, JAG2, JAK2, KLF6, KLK8, LCN2, MAP2K5, MT3, NFIB, NOS3, NOS2A, NR3C2, PDGFA, RARA, REG1A, REG3A, RNMT, SDC2, ST6GAL1, STAT1, TIMP1, TPM3, USF1, VDR, VIPR1 3.82 × 10-3 AGTR1, AKR1C3, BDNF, CALCA, CD44, CHRM3, DDR1, FN1, GDF15, GRK5, NPPC, NRG1, PPIA, PTPN11, TAC1, TGFB1
Cellular Movement
Cell movement 2.18 × 10-8 ADCYAP1, ANXA1, CASP1, CDC42, CHRM3, CHRM4, CXCL10, CXCL13, EGR1, FCGR2A, FER, FGB, FGFR1, GNAZ, GRID2, HGF, HLA-G, HSP90AB1, IGF2R, JAK2, LCN2, LGALS9, LIMS1, MAP2K5, MST1, NOS3, NOS2A, OLR1, PDGFA, RARA, REG3A, SDC2, ST6GAL1, STAT1, TIMP1, TPM3, TUBB, VDR, VIPR1 7.96x10-5 ADAM17, AGTR1, APCS, BDNF, CALCA, CASP1, CD44, CHRM3, DDR1, FN1, GJB2, GNAZ, GRID2, LCAT, LIMS1, NAP1L4, NPPC, NRG1, PDE4B, PPIA, PTPN11, SCN2B, SELP, SLC1A3, TAC1, TGFB1, TPM1
Chemotaxis 4.05 × 10-4 ANXA1, CDC42, CXCL10, CXCL13, FCGR2A, FER, FGFR1, GNAZ, HGF, IGF2R, LGALS9, NOS3, VIPR1 6.29x10-5 AGTR1, BDNF, CALCA, CD44, FN1, GNAZ, NAP1L4, PDE4B, PPIA, PTPN11, SCN2B, TAC1, TGFB1
Cell-To-Cell Signaling and Interaction
Adhesion of cells 1.47 × 10-7 ANXA1, CDC42, CDH17, CXCL10, EGR1, FCGR2A, FER, FEZ1, FGB, FGFR1, FGG, GRID2, HGF, IGF2R, ITGA7, JAG2, LGALS9, LIMS1, NOS3, OLR1, REG3A, SDC2, ST6GAL1, STAT1, STX4, TIMP1 1.34x10-4 ACHE, ADAM17, CASK, CD44, CNTN4, DDR1, DLG1, FGG, FN1, GRID2, LIMS1, NRG1, PTPN11, SELP, STX4, TAC1, TGFB1, TPH1
Cell Signaling
Quantity of calcium 3.25 × 10-3 ADCYAP1, AVP, CHRM3, CXCL10, CXCL13, FCGR2A, GHRH, HGF, NOS3, NOS2A, VDR 8.89x10-6 AGTR1, BDNF, CALCA, CHRM3, FN1, GRK5, NPPC, PLD2, PPIA, PTHR1, PTPN11, SELP, TAC1, TGFB1
Production of nitric oxide 1.33 × 10-3 IRF1, JAK2, MST1, NOS3, NOS2A, STAT1 - -
Flux of calcium 1.67 × 10-3 ADCYAP1, ANXA1, AVP, CHRM3, CXCL10, CXCL13, FCGR2A, P2RX2 2.20x10-3 CALCA, CHRM3, FN1, NPPC, P2RX2, PPIA, TGFB1
Cell surface receptor linked signal transduction 1.45 × 10-3 ACVR2A, ANXA1, CDC42, CXCL10, FCGR2A, FGFR1, ITGA7, JAK2, KLF6, LIMS1, PDGFA, PTPRD, STAT1 - -
Small Molecule Biochemistry
Quantity of cyclic AMP 1.00 × 10-5 ADCYAP1, AVP, CHRM4, CXCL10, GAP43, GHRH, GNAZ, NOS3, VIPR1 6.03x10-3 BDNF, CALCA, GNAZ, NPPC, PTHR1
Production of cyclic AMP 2.17 × 10-4 ADCYAP1, AVP, GHRH, GNAZ, NOS3, NOS2A, VIPR1
Accumulation of cyclic AMP 1.21 × 10-3 ADCYAP1, AVP, AVPR2, CHRM3, GHRH, VIPR1 4.35 × 10-4 CALCA, CHRM3, GRK5, PTHR1, TAC1, TGFB1
Formation of cyclic AMP 1.28 × 10-4 ADCYAP1, AVP, AVPR2, GHRH, GANZ 7.26 × 10-4 CALCA, GNAZ, PTHR1, TAC1
Release of Ca2+ 9.82 × 10-5 ANXA1, AVP, CHRM3, FCGR2A, FGB, FGG - -
Quantity of cholesterol - - 2.85 × 10-3 ATP7B, BDNF, CALCA, GULO, LCAT
Post-Translational Modification
Modification of protein 1.57 × 10-5 AVP, BRCA1, CASP1, CHRM3, FCGR2A, FER, FGFR1, GRID2, HSP90AB1, HTATIP, JAK2, LHB, MST1, NOS3, NOS2A, PDGFA, PDIA2, PDP2, PIM3, PTPRD, ST6GAL1, STAT1, TGM1 4.47 × 10-3 APCS, CASP1, CD44, CHRM3, DUSP6, FN1, GRID2, NDST1, NRG1, PDIA3, PPIA, PTPN11, RABGGTA, TAC1, UBB
Nervous system development and function
growth of neurites 8.02 × 10-3 ADCYAP1, CDC42, GAP43, HGF, TPM3 - -
survival of neurons 3.60 × 10-3 ADCYAP1, BCL2L11, GDF15, HGF, RARA, REG3A - -
development of synapse 6.57 × 10-3 GRID2, NFASC - -
fasciculation of axons 3.14 × 10-2 GAP43 - -
complexity of dendritic trees 1.25 × 10-2 HGF - -
long-term potentiation of dentate gyrus 1.25 × 10-2 EGR1 - -
neurological process of synapse - - 1.60 × 10-4 BDNF, CHRM3, CHRNB1, NRG1, PPP1R1A
synaptic transmission - - 2.88 × 10-4 BDNF, CACNB2, CHRM3, CHRNB1, GABRG2, P2RX2, SCN2B, SLC1A1, SLC1A3
neurological process of axons, neurites - - 4.79 × 10-4 BDNF, CNTN4, GRID2, NRG1, PDIA3, UBB
activation of nerves - - 7.73 × 10-4 CALCA, TAC1
binding of neurites - - 7.73 × 10-4 BDNF, CD44
size of cell body - - 7.73 × 10-4 ACHE, BDNF
survival of neurons - - 8.92 × 10-4 BDNF, GDF15, NRG1, PDIA3, SLC1A3, TGFB1
development of neurites - - 2.83 × 10-3 ACHE, BDNF, GRID2, NRG1, PDIA3, PTPN11
migration of nervous tissue cell lines - - 3.38 × 10-3 NRG1, TGFB1
proliferation of nervous tissue cell lines - - 6.67 × 10-3 NPPC, TGFB1

-, no subcategories found in IPA Tool; p-values and gene symbols are from IPA Tool

Discussion

In a previous study, we have used PC12 cells to examine the effects of IL-6/s-IL6R on neuronal differentiation in comparison to NGF [22]. Already after 24 hours of exposure to IL-6/s-IL-6R or NGF PC12 cells are highly active in cellular growth and proliferation displaying pronounced formation of extending neurites. Combined incubation with IL-6/s-IL-6 plus NGF drastically enhanced cell number and neurite outgrowth arguing for an additive effect of both stimuli on neuronal differentiation. In the current study we have chosen this time point to perform microarray analyses in order to monitor changes in gene expression and to compare the genetic programs utilized for neuronal differentiation by IL-6 versus NGF.

An important aspect in gene expression profiling using microarrays is the accuracy of the measurements in the relative changes in mRNA expression. Thus, alternative technologies such as qRT-PCR are used for the validation of microarray data [27]. Several systematic studies comparing the changes in gene expression obtained from oligonucleotide- or cDNA arrays to data from qRT-PCR revealed that a good correlation exists for genes exhibiting fold-change differences in expression of > 2-fold [28,29]. Therefore, in our datasets all genes displaying changes in expression levels of < 2-fold were excluded. Moreover, our exemplary validation data on GAP-43- and REG3B-expression are in line with other previous reports confirming that it is rather the magnitude of fold change varying between qRT-PCR and Affymetrix-analysis, but not the direction.

Detailed Ingenuity biological function analyses reveal that IL-6 and NGF activate gene sets that regulate the same process in neuronal differentiation and nervous system development, however, utilizing completely distinguished sets of individual molecules. This may explain our previous observation that combined application of IL-6/s-IL-6R plus NGF generates an additive effect on PC12 cell differentiation. Important processes in neuronal differentiation and nervous tissue development include cellular growth and proliferation in order to enhance cell number. Neurite outgrowth and network generation requires migration of neurons or nerve growth cones. Neuronal navigation is guided by the interaction of the neuron with its local environment, in particular by chemotaxis as the key mechanism. This process involves three major steps including directional sensing along a gradient of chemotactic factors, cellular motility i.e. the cell's movement by changes in cytoskleletal organisation and cellular adhesion and cellular polarisation [30-32]. Certainly, a key step in the regulation of these processes is the increased gene expression of growth factors and functionally related external molecules, indicating convergence of several different signaling pathways (Table 5). In IL-6 stimulated PC12 cells these tasks may be taken by growth differentiation factor 15 (GDF15), platelet-derived growth factor alpha (PDGFA), hepatocyte growth factor (HGF), regenerating islet-derived 3 alpha (REG3A), regenerating islet-derived 3 beta/pancreatitis-associated protein I (REG3B/PAPI), growth hormone releasing hormone (GHRH) and adenylate cyclase activating polypeptide (PACAP). NGF recruits GDF15 (131-fold), transforming growth factor beta 1 (TGFB1; 101-fold) and brain-derived neurotrophic factor (BDNF; 89-fold). TGFB1 is the prototype member of the TGFB-superfamily comprising multifunctional growth factors with numerous cell and tissue functions such as cell cycle control, regulation of early development, differentiation, extracellular matrix (ECM) formation and chemotaxis. In the nervous system, TGFB1 has been shown to regulate neuroprotection against glutamate cytotoxicity, ECM production, and cell migration in the cerebral cortex, control of neuronal death as well as survival of neurons (reviewed in [33]). GDF15 is a member of the TGFB- superfamily and has been shown to be a potent trophic factor in the brain (reviewed in [34]). Hepatocyte growth factor (HGF) is a chemoattractant and a survival factor for embryonic motor neurons. In addition, sensory and sympathetic neurons and their precursors respond to HGF with increased differentiation, survival and axonal outgrowth [35]. Moreover, HGF may synergize with other neurotrophic factors to potentiate the response of developing neurons to specific signals [36]. Platelet derived growth factor (PDGF) has been suggested to support neuronal differentiation [37], and has previously been reported to act as a mitogen for immature neurons [38] and neural progenitor cells [39]. REG3A and REG3B/PAPI are members of the regenerating protein (REG)/pancreatitis-associated protein (PAP) family representing a complex group of small secretory proteins which display many different functions, among them growth factor activity for neural cells [40]. So far, only limited knowledge is available about the role and function of PAP/REG-proteins in the nervous system. REG3B/PAPI expression is induced in spinal motor neurons as well as subsets of the dorsal root ganglion neurons [41]. Moreover, in vitro REG3B/PAPI has a mitogenic effect on Schwann cells [42]. In a hypoglossal nerve injury model in rats, expression of REG3B/PAPI mRNA was found to be enhanced in injured motor neurons after axotomy and a marked induction of REG3G/PAPIII mRNA was observed in the distal part of the injured nerve [43]. More recently, REG3G/PAPIII has been identified as a macrophage chemoattractant that is induced in and released from injured nerves [44]. With REG1A/PSP and REG3G/PAPIII, two further members of the REG/PAP family are induced by IL-6 in PC12 cells. It is noteworthy that these genes are up-regulated at the highest levels obtained in the entire dataset for IL-6. In NGF-treated PC12 cells, no up-regulation of the PAP/REG protein genes was observed. The results in our study are in line with an earlier report demonstrating up-regulation of PAP/REG gene family members in PC12 cells upon stimulation with IL-6/s-IL-6R [45].

So far various studies have investigated gene expression profiles in NGF-treated PC12 cells applying different experimental protocols in respect to time points and periods of NGF administration [46-51]. From most studies, it is obvious that PC12 cells require at least 3 to 5 days of NGF-treatment to obtain the fully differentiated neuronal phenotype. The most significant morphological changes occur within the first 2 days, reaching a plateau phase at day 3 [51]. Redundant data sets as well as unique genes have been identified and followed. Our study provides novel candidate genes activated in the early phase of the differentiation process and thus may enlarge the repertoire of known NGF-regulated genes.

The current study reveals novel aspects of IL-6 action, notably that it applies several major routes to direct PC12 cell differentiation. Besides up-regulation of growth factors known to act in autocrine and paracrine fashion to take over further tasks in the differentiation process, these include induction of PACAP, a pleiotropic molecule with a broad spectrum of biological functions. Among them are actions as a neurotrophic factor similar to NGF as well as induction of transcription factors known to be of key importance in neuronal differentiation [52].

Upregulation of PACAP could have an important impact on IL-6-induced PC12 cell differentiation. A recent report provided data from microarray analyses of PACAP-regulated gene transcripts in primary cultures of sympathetic neurons at 6 hours and 92 hours of stimulation [53]. A comparison with our data reveals that many gene families that are activated by PACAP in primary sympathetic neurons are also induced by IL-6 in PC12 cells (Table 6). Thus, many of the effects of IL-6 on PC12 cells are likely to be mediated by the intermediate autocrine and/or paracrine action of PACAP. PACAP is a member of a family of neuropetides known to activate class II G-protein coupled receptors (GPCRs; reviewed in [54]). Other family members include growth hormone releasing hormone (GHRH) and calcitonin-related peptide beta (CALCB) which are activated by IL-6 in PC12 cells by 31-and 195-fold, respectively. All members of the class II GPCR superfamily regulate intracellular cAMP-levels by receptor coupling to the Gs-adenylate cyclase-cAMP signaling pathway [54]. A further mechanism of PACAP action in PC12 cells could be a transactivation of TrkA receptors [55]. However, in light that the overlap in the datasets of IL-6 versus NGF is rather small, TrkA activation may not be a primary event at all or at the time point of our study.

Table 6.

Comparison of commonly regulated gene families in PACAP-stimulated sympathetic primary neurons versus IL-induced PC12 cells (data derived from [53])

PACAP-stimulated sympathetic neurons (data are from [53]) IL-6-stimulated PC12 cells
Gene family
Gene abbreviation 9 hours 96 hours Gene abbreviation 24 hours
Pituitary adenylate cyclase activating polypeptide
ADCYAP1 + + ADCYAP1 +
BCL2-like protein
BCL2L11 + n.c. BCL2L11 +
Chemokine Ligands
CXCL1 + +
CXCL10 +
CXCL13 +
Cytochrome P450 proteins
CYP1B1 + +
CYP4F16 +
Early growth response
EGR1 + n.c. EGR1 +
Glutathione S-transferase
GSTA3 + n.c. GSTA3 -
Heat shock proteins
HSP27B1 + n.c. HSP90B1 +
Janus kinase
JAK2 + JAK2 +
Kruppel-like factors
KLF4 + n.c. KLF6 +
KLF9 + n.c.
Nuclear factors
NFIA + n.c. NFIB +
Nuclear receptors
NR4A3 + n.c.
NR4A2 + n.c.
NR4A1 + n.c.
NR3C2 +
Sialytransferases
ST8SIA1 + + ST8SIA3 -
ST6GAL1 + + ST6GAL1 +
Solute carrier proteins
SLC1A3 + n.c.
SLC2A1 +
SLC2A3 + +
SLC6A3 +
SLC7A1 + +
SLC7A3 +
SLC12A5 -
SLC18A2 + +
SLC30A2 -
SLC24A2 +
Tubulins
TUBA1 - n.c.
TUBB +
Tissue Inhibitor of metalloproteinase
TIMP1 + + TIMP1 +

+, upregulated -, downregulated; n.c., not changed from control cultures; gene symbols are from IPA Tool

A further key step in IL-6 actions on PC12 cell differentiation is the induction of RARA and EGR-1/Zif268, two transcription factors known to be of crucial importance in neuronal differentiation. Among the genes regulated by retinoic acid is GAP-43, a neuron specific protein frequently used as a marker of neuronal differentiation as it is expressed in most neurons during neuronal development, nerve regeneration and LTP [56-60]. The data herein are confirmative to our previous study in which we have found induction of GAP-43 mRNA upon stimulation of PC12 cells with IL-6/s-IL-6R [22]. EGR-1/Zif268 is induced in nearly every model of long-lasting synaptic plasticity in the CNS [61-64] and suppression of Zif268 prevents neurite outgrowth in PC12 cells [65]. Recently candidate target genes of Zif268 in PC12 cells were identified suggesting that a key component of the long-lasting effects of Zif268 on CNS plasticity is the regulation of proteasome activity [66,67].

Signal transducer and activator of transcription 1/2 (STAT1/2), two members of the STAT family of transcriptions factors involved in signaling by Interferons (IFN) [68] are activated by stimulation of the PC12 cells with IL-6. As we could not detect changes in IFN gene expression, an autocrine action of PDGF is the most likely candidate for upregulation of STAT1/2 as described for neural progenitor cells [39]. STAT1/2 may upregulate interferon regulatory factor 1(IRF1)-expression, a further transcription factor of IFN-signaling. Breast cancer 1 (BRCA1) encodes a tumour suppressor gene whose germ line mutations in women are associated with a genetic predisposition to breast and ovarian cancer. STAT1 transcriptional activity is decreased by a physical interaction with BRCA1 as a key step in the regulation of IFN-induced cellular growth arrest [69]. By the action of IL-6, BRCA1 gene expression is down-regulated thus supporting STAT1 mediated PC12 cell growth. We failed to detect STAT3 expression, the key transcription factor of IL-6 signaling. This is most likely due to the fact that STAT3 gene transcription occurs very early in IL-6-stimulation and is already terminated at the time point of the analysis, or the expression levels are below 2-fold and thus did not meet the exclusion criteria.

The morphological changes during nervous system development are controlled by interactions of individual neurons with the ECM. Signals from the ECM into a particular neuron are mediated by integrins via associated adapter molecules. In this way growth factor induced receptor tyrosine kinase (RTK)- and integrin-mediated signalling determine the fate of a particular cell, notably differentiation, cell shape, adhesion, polarity, migration, as well as proliferation versus apoptotic cell death (reviewed in [70]). LIM and senescent cell antigen-like domains1/PINCH (LIMS1/PINCH) is an intracellular adaptor molecule providing the molecular link of an integrin-RTK network. LIMS1 physically connects integrin-linked kinase (ILK) to non-catalytic (region of) tyrosine kinase adaptor protein 2 (Nck2), an adapter molecule of the growth factor receptor (RTK) [70]. LIMS1 is activated by IL-6 as well as NGF and thus is one of few genes regulated in the common subset. In contrast to IL-6, NGF simultaneously up-regulates major components of the ECM including collagen, type XI, alpha1 (COL11A1), COL12A1, fibronectin1 (FN1) as well as fibrillin2 (FN2) (Table 2).

In contrast to NGF, only one publication provided expression profiling data analysing gene sets regulated by IL-6 upon neuronal differentiation. Primary cultures of rat dorsal root ganglia (DRG) were treated with IL6RIL6 for 2 and 4 days, respectively. A detailed comparison reveals that only a small number of commonly regulated genes may be identified in the datasets that are regulated in parallel or opposite direction. These include Egr-1 (upregulated in PC12 cells; downregulated in DRG cells), TGFA (upregulated in PC12 cells and DRG cells), TGFB (upregulated in PC12 cells; downregulated in DRG cells), PDGFA (upregulated in PC12 cells; downregulated in DRG cells) and IRF-1 (upregulated in PC12 cells and in DRG cells) [24].

The results obtained from our study may also have impact into clinical treatments of injured peripheral nerves which, in contrast to central nerves, have the ability to recover from damage. Currently the therapy of choice is the use of autologous grafts where the defect is bridged with a section of autologous nerve tissue, mostly a sensory nerve [71]. Alternatively, nerve conduits or decellularized nerve grafts can be used; however, no therapy could yield a satisfactory functional recovery [72]. Various combinations of NTs, neuropoietic cytokines and GFLs have been shown to generate a microenvironment suitable to improve nerve repair [26]. The results of our study may provide novel aspects for the treatment of peripheral nerve injury as the local application of a designer cytokine such as H-IL-6 with a strongly enhanced bioactivity on neuronal development and neurite outgrowth in combination with NTs and/or GFLs may create a microenvironment with a strong reparative potency.

Conclusion

IL-6 and NGF utilize different genetic programs to exert the same biological functions in neuronal differentiation. An important step is the recruitment of many growth factors that may act in autocrine and/or paracrine fashion and may control the long-term effects on growth, neuronal differentiation or survival.

Methods

Reagents, buffers and cells

DMEM medium, horse serum, fetal bovine serum and other cell culture supplements were obtained from GibcoBRL. TRIZOL reagent and Superscript reverse transcriptase were purchased Life Technologies. PC12 cells were obtained from ATCC, Manassas (VA), USA. Hyper-IL-6 was generated as described [8]. The LightCycler PCR kit was from Roche Diagnostics, Mannheim, Germany.

Cell culture

PC12 cells were cultured in DMEM medium containing 10% fetal bovine serum and 100 U/ml penicillin and streptomycin at 37°C in humidified 5% CO2/95% air. For stimulation confluent cells were washed once with PBS and cultured in cell culture medium containing 10 ng/ml H-IL-6 or 50 ng/ml recombinant human NGF for 24 hours. Control cells were incubated in cell culture medium alone for 24 hours.

RNA Preparation

Total RNA from unstimulated (control), H-IL-6- and NGF- stimulated PC12 cells was isolated using TRIZOL reagent according to the manufacturer's instructions. RNA was quantified spectrophotometrically by measuring the absorbance at 260 nm and the integrity was checked by formaldehyde agarose gel electrophoresis. The extracted RNA was stored at -80°C.

GeneChip analysis

20 μg of total RNA was used for each experiment and the target cRNA for Affymetrix Gene Chip analysis was prepared according to the manufacturer's instructions. Affymetrix GeneChip Rat Genome U34A arrays containing each 8'799 probes including full-length or annotated rat genes and several thousands of rat EST clusters consisting of redundant probes spanning an identical transcript were hybridized with the target cRNAs at 45°C for 16 h, washed and stained by using the Gene Chip Fluidics Station. The arrays were scanned with the Gene Array scanner (Affymetrix), and the fluorescence images obtained were processed by the Expression Analysis algorithm in Affymetrix Microarray Suite (ver. 4.0) and Microsoft Excel. Data were imported into GeneSpring® analysis software (ver. 4.1.3, Silicon Genetics, Redwood City, CA) for further analysis. Genes that showed substantial up- or down-regulation after stimulation by fold changes > 2 were selected from three independent experiments. Genes whose fold change was < 2 and expressed sequence tags (ESTs) that were not fully identified were excluded from the gene list. Thus, only genes with a change fold cutoff > 2 were considered to be significantly differentially regulated. Values are given as round off numbers. For each condition (unstimulated control- and H-IL-6-simulated PC12 cells or unstimulated control and NGF-stimulated PC12 cells) 3 independent microarray analyses (n = 3) were performed using RNA samples derived from independently prepared cell culture batches.

Quantitative Real Time PCR (qRT-PCR)

Total RNA (10 μg) from individual samples cultured separately from those used for microarray analyses was reverse-transcribed using Superscript II Reverse Transcriptase (GibcoBRL) according to the manufacturer's instructions.

PCR reactions were performed in glass capillaries with the LightCycler thermal cycler system (Software version 3.5; Roche Diagnostics, Mannheim, Germany) using the LightCycler DNA Master SYBR Green I kit (Roche Diagnostics, Mannheim) according to the manufacturer's instructions. The primers used for RT-PCR analyses were rat S12 forward: 5'-GGC ATA GCT GCT GGA GGT GTA A-3'; rat S12 reverse: 5'-CCT TGG CCT GAG ATT CTT TGC-3'; rat REG3B forward: 5'-GGT TTG ATG CAG AAC TGG CCT-3'; rat REG3B reverse: 5'-TGA CAA GCT GCC ACA GAA TCC-3'; rat GAP-43 forward: 5'-CGT TGC TGA TGG TGT GGA GAA-3'; rat GAP-43 reverse: 5'-GCA GGC ACA TCG GCT TGT TTA-3'. PCR conditions were: 50 cycles with denaturation at 95°C for 8 seconds, annealing at 57°C for 8 seconds, and extension at 72°C for 14 seconds. Negative controls without cDNA (non-template controls; ntc) were run concomitantly. Specificity of amplified PCR products was confirmed by melting curve analysis after completion of the PCR run. Each PCR was performed in 3 independent experiments (n = 3) using different cell-culture batches.

Quantification of LightCycler qRT-PCR data

Quantification of data was performed with the LightCycler software 3.3 (Roche Diagnostics) using the ΔΔCp method. The difference between the crossing points (CPs; ΔCp values) for the target mRNA samples and reference S12 RNA samples (ΔΔCp) was used to calculate the expression values of the target mRNAs (2-Δ(ΔCp)).

Ingenuity global functional analyses

To investigate possible biological interactions of differently regulated genes, datasets representing genes with altered expression profile derived from microarray analyses were imported into the Ingenuity Pathway Analysis Tool (IPA Tool; Ingenuity®Systems, Redwood City, CA, USA; http://www.ingenuity.com). The basis of the IPA-program consists of the Ingenuity Pathway Knowledge Base (IPKB) which is derived from known functions and interactions of genes published in the literature. Thus, the IPA Tool allows the identification of biological networks, global functions and functional pathways of a particular dataset. The complete dataset containing gene identifiers (Genbank accession numbers) and corresponding expression values was uploaded into the application. Each gene identifier is mapped to its corresponding gene object in the IPKB. Each gene product is assigned to functional (e.g. "cellular growth and proliferation") and sub-functional (e.g. "colony formation") categories. The biological functions that are most significant to the dataset are identified by the use of Fischer's exact test to calculate a p-value that determines the probability that each biological function assigned to that data set is due to chance alone.

Statistical analysis

Differences were tested by Welch's t-test based on three independent experiments, and p-values less than 0.05 were considered statistically significant. Values are expressed as means ± SEM.

Authors' contributions

DK and GW generated the microarray data and drafted the manuscript. UC provided the microarray facility. MB performed the statistical analyses of the microarrays. BD and PM performed the cell-culture of PC12 cells. DK and UO provided support, direction and oversight of the experiments and revised the final manuscript. UO holds the SNF grant.

Acknowledgments

Acknowledgements

The authors would like to thank Prof. Dr. Stefan Rose-John, University of Kiel, Germany, for kindly providing recombinant H-IL-6. This work was supported by a grant of the Swiss National Science Foundation (SNF; grant nr.3200BO-100730).

Contributor Information

Dieter Kunz, Email: dieter.kunz@unibas.ch.

Gaby Walker, Email: gaby.walker@roche.com.

Marc Bedoucha, Email: marc.bedoucha@roche.com.

Ulrich Certa, Email: ulrich.certa@roche.com.

Pia März-Weiss, Email: pia.maerz-weiss@roche.com.

Beatrice Dimitriades-Schmutz, Email: beatrice.dimitriades@unibas.ch.

Uwe Otten, Email: uwe.otten@unibas.ch.

References

  1. Taga T, Kishimoto T. gp 130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797–819. doi: 10.1146/annurev.immunol.15.1.797. [DOI] [PubMed] [Google Scholar]
  2. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007;8:221–232. doi: 10.1038/nrn2054. [DOI] [PubMed] [Google Scholar]
  3. Rose-John S, Heinrich P. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300:281–290. doi: 10.1042/bj3000281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Müllberg J, Althoff K, Jostock T, Rose-John S. The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw. 2000;11:27–38. [PubMed] [Google Scholar]
  5. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci USA. 2005;102:9589–9594. doi: 10.1073/pnas.0501794102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Rose-John S. Coordination of interleukin-6 biology by membran-bound and soluble receptors. Adv Exp Med Biol. 2001;495:145–151. doi: 10.1007/978-1-4615-0685-0_19. [DOI] [PubMed] [Google Scholar]
  7. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 Transsignaling: The In Vivo Consequences. J Interferon Cytokine Res. 2005;25:241–253. doi: 10.1089/jir.2005.25.241. [DOI] [PubMed] [Google Scholar]
  8. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol. 1997;15:142–145. doi: 10.1038/nbt0297-142. [DOI] [PubMed] [Google Scholar]
  9. Peters M, Blinn G, Solem F, Fischer M, Meyer zum Buschenfelde KH, Rose-John S. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol. 1998;161:3575–3581. [PubMed] [Google Scholar]
  10. Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets. 2008;7:46–62. doi: 10.2174/187152708783885174. [DOI] [PubMed] [Google Scholar]
  11. Lee FS, Rajagopal R, Chao MV. Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors. Cytokine Growth Factor Rev. 2002;13:11–17. doi: 10.1016/s1359-6101(01)00024-7. [DOI] [PubMed] [Google Scholar]
  12. Rossi C, Angelucci A, Costantin L, Braschi C, Mazzantini M, Babbini F, Fabbri ME, Tessarollo L, Maffei L, Berardi N, Caleo M. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur J Neurosci. 2006;24:1850–1856. doi: 10.1111/j.1460-9568.2006.05059.x. [DOI] [PubMed] [Google Scholar]
  13. Gorski JA, Balogh SA, Wehner JM, Jones KR. Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience. 2003;121:341–354. doi: 10.1016/s0306-4522(03)00426-3. [DOI] [PubMed] [Google Scholar]
  14. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung WH, Hempstead BL, Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487–491. doi: 10.1126/science.1100135. [DOI] [PubMed] [Google Scholar]
  15. Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron. 2002;33:9–12. doi: 10.1016/s0896-6273(01)00573-6. [DOI] [PubMed] [Google Scholar]
  16. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609–642. doi: 10.1146/annurev.biochem.72.121801.161629. [DOI] [PubMed] [Google Scholar]
  17. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6:603–614. doi: 10.1038/nrn1726. [DOI] [PubMed] [Google Scholar]
  18. Satoh T, Nakamura S, Taga T, Matsuda T, Hirano T, Kishimoto T, Kaziro Y. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol. 1988;8:3546–3549. doi: 10.1128/mcb.8.8.3546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Abeyama K, Kawano K, Nakajima T, Takasaki I, Kitajima I, Maruyama I. Interleukin 6 mediated differentiation and rescue of cell redox in PC12 cellsexposed to ionizing radiation. FEBS Lett. 1995;364:298–300. doi: 10.1016/0014-5793(95)00412-3. [DOI] [PubMed] [Google Scholar]
  20. Kotake-Nara E, Takizawa S, Quan J, Wang H, Saida K. Cobalt chloride induces neurite outgrowth in rat pheochromocytoma PC12 cells through regulation of endothelin-2/vasoactive intestinal contractor. J Neurosci Res. 2005;81:563–571. doi: 10.1002/jnr.20568. [DOI] [PubMed] [Google Scholar]
  21. März P, Cheng JC, Gadient RA, Patterson P, Stoyan T, Otten U, Rose-John S. Sympathetic neurons can produce and respond to interleukin-6. Proc Natl Acad Sci USA. 1998;95:3251–3256. doi: 10.1073/pnas.95.6.3251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. März P, Herget Th, Lang E, Otten U, Rose-John S. Activation of gp130 by IL-6/soluble IL-6 receptor induces neuronal differentiation. Eur J Neurosci. 1998;10:2765–2773. doi: 10.1111/j.1460-9568.1997.tb01705.x. [DOI] [PubMed] [Google Scholar]
  23. März P, Otten U, Rose-John S. Neuronal activities of IL-6 type cytokines often depend on soluble cytokine receptors. Eur J Neurosci. 1999;11:2995–3004. doi: 10.1046/j.1460-9568.1999.00755.x. [DOI] [PubMed] [Google Scholar]
  24. Zhang PL, Levy AM, Ben-Simchon L, Haggiag S, Chebath J, Revel M. Induction of neuronal and myelin-mediated gene expression by IL6receptor/IL-6: A study on embryonic dorsal root ganglia cells and isolated Schwann cells. Exp Neurol. 2007;208:285–296. doi: 10.1016/j.expneurol.2007.08.022. [DOI] [PubMed] [Google Scholar]
  25. Gordon Boyd GJ, Gordon T. Neurotrophic Factors and Their Receptors in Axonal Regeneration and Functional Recovery After Peripheral Nerve Injury. Mol Neurobiol. 2003;27:277–324. doi: 10.1385/MN:27:3:277. [DOI] [PubMed] [Google Scholar]
  26. Deister C, Schmidt CE. Optimizing neurotrophic factor combinations for neurite outgrowth. J Neural Eng. 2006;3:172–179. doi: 10.1088/1741-2560/3/2/011. [DOI] [PubMed] [Google Scholar]
  27. Mimmack ML, Brooking J, Bahn S. Quantitative polymerase chain reaction: validation of microarray results from postmortem brain studies. Biol Psychiatry. 2004;55:337–345. doi: 10.1016/j.biopsych.2003.09.007. [DOI] [PubMed] [Google Scholar]
  28. Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC. Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res. 2002;30:e48. doi: 10.1093/nar/30.10.e48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry PA, Freitas JR, Boag JM, Cummings AJ, Kees UR. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR- how well do they correlate? BMC Genomics. 2002;6:59. doi: 10.1186/1471-2164-6-59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Song HJ, Poo Mm. The cell biology of neuronal navigation. Nat Cell Biol. 2001;3:E81–E88. doi: 10.1038/35060164. [DOI] [PubMed] [Google Scholar]
  31. Van Haastert PJM, Devreotes PN. Chemotaxis: Siganlling the way forward. Nat Rev Mol Cell Bio. 2004;5:626–634. doi: 10.1038/nrm1435. [DOI] [PubMed] [Google Scholar]
  32. Mortimer D, Fothergill T, Pujic Z, Richards LJ, Goodhill GJ. Growth cone chemotaxis. Trends Neurosci. 2008;31:90–98. doi: 10.1016/j.tins.2007.11.008. [DOI] [PubMed] [Google Scholar]
  33. Gomes FC, Sousa Vde O, Romão L. Emerging roles for TGF-beta1 in nervous system development. Int J Dev Neurosci. 2005;23:413–424. doi: 10.1016/j.ijdevneu.2005.04.001. [DOI] [PubMed] [Google Scholar]
  34. Kriegelstein K, Strelau J, Schober A, Sullivan A, Unsicker K. TGF-beta and the regulation of neuron survival and death. J Physiol Paris. 2002;96:25–30. doi: 10.1016/s0928-4257(01)00077-8. [DOI] [PubMed] [Google Scholar]
  35. Kato M, Yoshimura S, Kokuzawa J, Kitajima H, Kaku Y, Iwama T, Shinoda J, Kunisada T, Sakai N. Hepatocyte growth factor promotes neuronal differentiation of neural stem cells derived from embryonic stem cells. javascript:AL_get(this, 'jour', 'Neuroreport.') Neuroreport. 2004;15:5–8. doi: 10.1097/00001756-200401190-00002. [DOI] [PubMed] [Google Scholar]
  36. Thompson J, Dolcet X, Hilton M, Tolcos M, Davies AM. HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Mol Cell Neurosci. 2004;27:441–452. doi: 10.1016/j.mcn.2004.07.007. [DOI] [PubMed] [Google Scholar]
  37. Williams B, Park J, Alberta J, Muhlebach SG, Hwang GY, Roberts TM, Stiles CD. A PDGF-regulated immediate early gene response initiates neuronal differentiation in ventricular zone progenitor cells. Neuron. 1997;18:553–562. doi: 10.1016/s0896-6273(00)80297-4. [DOI] [PubMed] [Google Scholar]
  38. Erlandsson A, Enarsson M, Forsberg-Nilsson K. Immature neurons from CNS stem cells proliferate in response to PDGF. J Neurosci. 2001;21:3483–3491. doi: 10.1523/JNEUROSCI.21-10-03483.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Erlandsson A, Braennvall M, Gustafsdottir S, Westermark B, Forsberg-Nilsson K. Autocrine/Paracrine Platelet-Derived Growth Factor Regulates Proliferation of Neural Progenitor Cells. Cancer Res. 2006;66:8042–8048. doi: 10.1158/0008-5472.CAN-06-0900. [DOI] [PubMed] [Google Scholar]
  40. Zhang YW, Ding LS, Lai MD. Reg gene family and human diseases. World J Gastroenterol. 2003;9:2635–2641. doi: 10.3748/wjg.v9.i12.2635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Livesey FJ, O-Brien JA, Li M, Smith AG, Murphy LJ, Hunt SP. A Schwann cell mitogen accompanying regeneration of motor neurons. Nature. 1997;390:614–618. doi: 10.1038/37615. [DOI] [PubMed] [Google Scholar]
  42. Averill S, Davis DR, Shortland PJ, Priestley JV, Hunt SP. Dynamic pattern of reg-2 expression in rat sensory neurons after peripheral nerve injury. J Neurosci. 2002;22:7493–7501. doi: 10.1523/JNEUROSCI.22-17-07493.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Namikawa K, Fukushima M, Murakami K, Suzuki A, Takasawa S, Okamoto H, Kiyama H. Expression of Reg/PAP family members during motor nerve regeneration in rat. Biochem Biophys Res Commun. 2005;332:126–134. doi: 10.1016/j.bbrc.2005.04.105. [DOI] [PubMed] [Google Scholar]
  44. Namikawa K, Okamoto T, Suzuki A, Konishi H, Kiyama H. Pancreatitis-associated protein-III is a novel macrophage chemoattractant implicated in nerve regeneration. J Neurosci. 2006;26:7460–7467. doi: 10.1523/JNEUROSCI.0023-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Broekaert D, Eyckerman S, Lavens D, Verhee A, Waelput W, Vandekerckhove J, Tavernier J. Comparison of leptin- and interleukin-6-regulated expression of the rPAP gene family: evidence for differential co-regulatory signals. Eur Cytokine Netw. 2002;13:78–85. [PubMed] [Google Scholar]
  46. Lee NH, Weinstock KG, Kirkness EF, Earle-Hughes JA, Fuldner RA, Marmaros S, Glodek A, Gocayne JD, Adams MD, Kerlavage AR, Fraser CM, Venter JC. Comparative expressed-sequence-tag analysis of differential gene expression profiles in PC-12 cells before and after nerve growth factor treatment. Proc Natl Acad Sci USA. 1995;92:8303–8307. doi: 10.1073/pnas.92.18.8303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Mayumi K, Yaoi T, Kawai J, Kojima S, Watanabe S, Suzuki H. Improved restriction landmark cDNA scanning and its application to global analysis of genes regulated by nerve growth factor in PC12 cells. Biochim Biophys Acta. 1998;1399:10–18. doi: 10.1016/s0167-4781(98)00081-5. [DOI] [PubMed] [Google Scholar]
  48. Brown AJH, Hutchings C, Burke JF, Mayne LV. Application of a rapid method (targeted display) for the identification of differentially expressed mRNAs following NGF-induced neuronal differentiation in PC12 cells. Mol Cell Neurosci. 1999;13:119–130. doi: 10.1006/mcne.1999.0736. [DOI] [PubMed] [Google Scholar]
  49. Angelastro JM, Klimaschewski L, Tang S, Vitolo OV, Weissman TA, Donlin LT, Shelanski ML, Greene LA. Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling. Proc Natl Acad Sci USA. 2000;97:10424–10429. doi: 10.1073/pnas.97.19.10424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Lee KH, Ryu CJ, Hong HJ, Kim J, Lee EH. CDNA microarray analysis of nerve growth factor-regulated gene expression profile in rat PC12 cells. Neurochem Res. 2005;30:533–540. doi: 10.1007/s11064-005-2688-y. [DOI] [PubMed] [Google Scholar]
  51. Dijkmans TF, van Hooijdonk LW, Schouten TG, Kamphorst JT, Vellinga AC, Meerman JH, Fitzsimons CP, de Kloet ER, Vreugdenhil E. Temporal and functional dynamics of the transcriptome during nerve growth factor-induced differentiation. J Neurochem. 2008 doi: 10.1111/j.1471-4159.2008.05338.x. [DOI] [PubMed] [Google Scholar]
  52. Ravni A, Bourgault S, Lebon A, Chan P, Galas L, Fournier A, Vaudry H, Gonzalez B, Eiden LE, Vaudry D. The neurotrophic effects of PACAP in PC12 cells: control by multiple transduction pathways. J Neurochem. 2006;98:321–329. doi: 10.1111/j.1471-4159.2006.03884.x. [DOI] [PubMed] [Google Scholar]
  53. Braas KM, Schutz KC, Bond JP, Vizzard MA, Girard BM, May V. Microarray analyses of pituitary adenylate cyclase activating polypeptide (PACAP)-regulated gene targets in sympathetic neurons. Peptides. 2007;28:1856–1870. doi: 10.1016/j.peptides.2007.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Martin B, de Maturana RL, Brenneman R, Walent T, Mattson MP, Maudsley S. Class II G Protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Med. 2005;7:3–36. doi: 10.1385/nmm:7:1-2:003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Shah BH, Catt KJ. GPCR-mediated transactivation of RTKs in the CNS: mechanisms and consequences. Trends Neurosci. 2004;27:48–53. doi: 10.1016/j.tins.2003.11.003. [DOI] [PubMed] [Google Scholar]
  56. Saunders DE, Hannigan JH, Zajac CS, Wappler NL. Reversal of alcohol's effects on neurite extension and on neuronal GAP-43/B50, N-myc, and c-myc protein levels by retinoic acid. Brain Res Dev Brain Res. 1995;86:16–23. doi: 10.1016/0165-3806(95)00008-2. [DOI] [PubMed] [Google Scholar]
  57. Routtenberg A, Cantallops I, Zaffuto S, Serrano P, Namgung U. Enhanced learning after genetic overexpression of a brain growth protein. Proc Natl Acad Sci USA. 2000;97:7657–7662. doi: 10.1073/pnas.97.13.7657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci. 1997;20:84–91. doi: 10.1016/s0166-2236(96)10072-2. [DOI] [PubMed] [Google Scholar]
  59. Oestreicher AB, De Graan PN, Gispen WH, Verhaagen J, Schrama LH. B-50, the growth associated protein-43: modulation of cell morphology and communication in the nervous system. Prog Neurobiol. 1997;53:627–686. doi: 10.1016/s0301-0082(97)00043-9. [DOI] [PubMed] [Google Scholar]
  60. Rekart J, Meiri K, Routtenberg A. Hippocampal-Dependent Memory Is Impaired in Heterozygous GAP-43 Knockout Mice. Hippocampus. 2005;15:1–7. doi: 10.1002/hipo.20045. [DOI] [PubMed] [Google Scholar]
  61. Bozon B, Davis S, Laroche S. Regulated transcription of the immediate-early gene Zif268: mechanisms and gene dosage-dependent function in synaptic plasticity and memory formation. Hippocampus. 2002;12:570–577. doi: 10.1002/hipo.10100. [DOI] [PubMed] [Google Scholar]
  62. Bozon B, Kelly A, Josselyn SA, Silva AJ, Davis S, Laroche S. MAPK, CREB and Zif268 are all required for the consolidation of recognition memory. Philos Trans R Soc Lond B Biol Sci. 2003;358:805–814. doi: 10.1098/rstb.2002.1224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Davis S, Bozon B, Laroche S. How necessary is the activation of the immediate early gene Zif268 in synaptic plasticity and learning? Behav Brain Res. 2003;142:17–30. doi: 10.1016/s0166-4328(02)00421-7. [DOI] [PubMed] [Google Scholar]
  64. Jones MW, Errington ML, French PJ, Fine A, Bliss TV, Garel S, Charnay P, Bozon B, Laroche S, Davis S. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci. 2001;4:289–296. doi: 10.1038/85138. [DOI] [PubMed] [Google Scholar]
  65. Levkovitz Y, Baraban JM. A dominant negative Egr inhibitor blocks nerve growth factor-induced neurite outgrowth by suppressing c-Jun activation: role of an Egr/c-Jun complex. J Neurosci. 2002;22:3845–3854. doi: 10.1523/JNEUROSCI.22-10-03845.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. James AB, Conway AM, Morris BJ. Genomic profiling of the neuronal target genes of the plasticity-related transcription factor – Zif268. J Neurochem. 2005;95:796–810. doi: 10.1111/j.1471-4159.2005.03400.x. [DOI] [PubMed] [Google Scholar]
  67. James AB, Conway AM, Morris BJ. Regulation of the neuronal proteasome by Zif268 (Egr1) J Neurosci. 2006;26:1624–1634. doi: 10.1523/JNEUROSCI.4199-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. van Boxel-Dezaire AH, Stark GR. Cell type-specific signaling in response to interferon-gamma. Curr Top Microbiol Immunol. 2007;316:119–154. doi: 10.1007/978-3-540-71329-6_7. [DOI] [PubMed] [Google Scholar]
  69. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene. 2006;25:5854–5863. doi: 10.1038/sj.onc.1209872. [DOI] [PubMed] [Google Scholar]
  70. Hehlgans S, Haase M, Cordes N. Signalling via integrins: Implications for cell survival and anticancer stratgies. Biochim Biophys Acta. 2007;1775:163–180. doi: 10.1016/j.bbcan.2006.09.001. [DOI] [PubMed] [Google Scholar]
  71. Lee SK, Wolfe SW. Peripheral nerve injury and repair. J Am Acad Orthop Surg. 2000;8:243–252. doi: 10.5435/00124635-200007000-00005. [DOI] [PubMed] [Google Scholar]
  72. Lundborg G. A 25-year perspective of peripheral nerve surgery: evolving neuroscientific concepts and clinical significance. J Hand Surg [Am] 2000;25:391–414. doi: 10.1053/jhsu.2000.4165. [DOI] [PubMed] [Google Scholar]

Articles from BMC Genomics are provided here courtesy of BMC

RESOURCES